Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Which stocks are moving on Wednesday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity
Bluebird Bio revised its agreement with Carlyle and SK Capital, adding a $5 per share cash option for stockholders ahead of deal completion. 
Via Benzinga
Exploring bluebird bio's Earnings Expectations
Via Benzinga
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
BlueBird Shares Are Up Today: What's Going On?
Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd. 
Via Benzinga
Monday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Dow Tumbles Over 700 Points; US Services PMI Falls In February
Via Benzinga
Topics Stocks
Exposures US Equities
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Stocks Firmly Lower As Consumer Sentiment Weakens
The Dow Jones Industrial Average is headed for another sharp triple-digit drop to end the week. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Gapping stocks in Friday's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
These stocks are moving in today's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs. 
Via Benzinga
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies. 
Via Benzinga
Exposures Product Safety
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns. 
Via Benzinga
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have... 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene... 
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

"

"